Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cancer cells bypass replicative senescence, the major barrier to tumor progression, by using telomerase or alternative lengthening of telomeres (ALT) as telomere maintenance mechanisms (TMMs). Correlation between ALT and patient survival was demonstrated for high-grade astrocytomas. Transcription from subtelomeres produces telomeric repeat-containing RNA (TERRA), a natural inhibitor of telomerase activity (TA). This led us to evaluate correlations of TERRA and TMM with tumor grade and outcome in astrocytoma patients. SYBR Green real-time reverse transcription-polymerase chain reaction assays for quantitation of total and chromosome 2p and 18p specific TERRA levels were developed. Tumor samples from 46 patients with astrocytoma grade 2 to 4, tissue controls, and cell lines were assessed. TMMs were evaluated by measuring TA and by detecting long telomeres due to ALT. In glioblastoma multiforme (GBM) grade 4, total TERRA levels were similar to cell lines but 14-, 31-, and 313-fold lower compared with grade 3, grade 2, and nonmalignant tissue, respectively. Total TERRA levels differed from chromosomal levels. Low 2p TERRA levels correlated with dense promoter methylation of subtelomeric CpG islands, indicating that TERRA expression in gliomas may be chromosome specific and epigenetically regulated. Total TERRA levels correlated with diagnosis, with low or absent TA and the presence of ALT, and were tentatively associated with favorable patient prognosis in our cohort (P = .06). TA and short telomeres identified a subset of GBM with a median survival of only 14.8 months. TERRA and TA may be prognostic in astrocytic tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“TA is the predominant mechanism used by roughly 85% of human cancer [5], and its role in cancer has been the focus of many reviews [6,7].”
BackgroundTelomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279 · cited 1×
“extensive lengthening [10].”
Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2004) · Neuro-Oncology · doi:10.1215/s1152851704000055 · Cited by 56 · cited 1×
“Direct inhibition of telomerase enzymatic activity has shown efficiency against glioma cell lines and xenografts [42–44], and first telomerase-based cancer therapy approaches are tested in clinical studies [45].”
Background
Cited by
Novel classes of non-coding RNAs and cancer
Sana, J., Faltejskova, P., Svoboda, M., & Slaby, O. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-103 · Cited by 304
Nuclear respiratory factor 1 and endurance exercise promote human telomere transcription
Diman, A., Boros, J., Poulain, F., Rodriguez, J., Purnelle, M., Episkopou, H., Bertrand, L., Francaux, M., Deldicque, L., & Decottignies, A. (2016) · Science Advances · doi:10.1126/sciadv.1600031 · Cited by 101
Role of TERRA in the regulation of telomere length
Wang, C., Zhao, L., & Lu, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10528 · Cited by 89
Aschacher, T., Geisler, D., Lenz, V., Aschacher, O., Winkler, B., Schaefer, A.-K., Mitterbauer, A., Wolf, B., Enzmann, F. K., Messner, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415498 · Cited by 6
Metadata
- Authors
- Sampl, S., Pramhas, S., Stern, C., Preusser, M., Marosi, C., & Holzmann, K.
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 5
- Issue
- 1
- Pages
- 56-IN4
- ISSN
- 1936-5233 (ISSN-L)
- OpenAlex
- W2037053816
- Cited by
- 87
- References
- 3
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.